Publications by authors named "Theodore Spiro"

Claim this Profile
B
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Gary E Raskob, Walter Ageno, Gregory Albers, C Gregory Elliott, Jonathan Halperin, Theodore Spiro

J Am Heart Assoc· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study.
Alex C Spyropoulos, Gary E Raskob, Theodore E Spiro, Wentao Lu, Yoriko De Sanctis

TH Open· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.
Alex C Spyropoulos, Mark Goldin, Walter Ageno, Gregory W Albers, C Gregory Elliott, Theodore E Spiro

TH Open· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Alex C Spyropoulos, Gary E Raskob, Alexander T Cohen, Walter Ageno, Jeffrey I Weitz, Theodore E Spiro

Circulation· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.
Concetta Lipardi, C Gregory Elliott, Chiara L Sugarmann, Lloyd Haskell, Alex C Spyropoulos, Theodore Spiro

Clin Appl Thromb Hemost· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study.
Kari Kelton, Tim Klein, Dan Murphy, Mark Belger, Erik Hille, Theodore Spiro

Adv Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
Robert Ohsfeldt, Kari Kelton, Tim Klein, Mark Belger, Patrick L Mc Collam, Theodore Spiro

Clin Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Gary E Raskob, Alex C Spyropoulos, Theodore E Spiro, Wentao Lu, Zhong Yuan

J Am Heart Assoc· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients.
Gary E Raskob, Alex C Spyropoulos, Alexander T Cohen, Jeffrey I Weitz, Walter Ageno, Theodore E Spiro

J Am Heart Assoc· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
Isabel Reinecke, Alexander Solms, Stefan Willmann, Theodore E Spiro, Gary Peters

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
Alexander Solms, Stefan Willmann, Isabel Reinecke, Theodore E Spiro, Gary Peters

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, C Gregory Elliott, Jonathan L Halperin, Theodore E Spiro

J Am Coll Cardiol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
Jonathan W Cunningham, João Pedro Ferreira, Hsiaowei Deng, Stefan D Anker, William M Byra, Theodore E Spiro

JACC Heart Fail· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
Alex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Theodore E Spiro

Clin Appl Thromb Hemost· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Jeffrey I Weitz, Gary E Raskob, Alex C Spyropoulos, Theodore E Spiro, Yoriko De Sanctis

Thromb Haemost· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
Alex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, Colleen Peluso, Theodore E Spiro

TH Open· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
Alexander Solms, Matthias Frede, Scott D Berkowitz, Anne Hermanowski-Vosatka, Dagmar Kubitza, Theodore E Spiro

CPT Pharmacometrics Syst Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mandeep R Mehra, Muthiah Vaduganathan, Min Fu, João Pedro Ferreira, Stefan D Anker, Theodore E Spiro

Eur Heart J· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Barry Greenberg, James D Neaton, Stefan D Anker, William M Byra, John G F Cleland, Theodore E Spiro

JAMA Cardiol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Faiez Zannad, Stefan D Anker, William M Byra, John G F Cleland, Min Fu, Theodore E Spiro

N Engl J Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, C Gregory Elliott, Jonathan L Halperin, Theodore E Spiro

N Engl J Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Gary E Raskob, Alex C Spyropoulos, Julie Zrubek, Walter Ageno, Gregory Albers, Theodore Spiro

Thromb Haemost· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Alexandre Mebazaa, Theodore E Spiro, Harry R Büller, Lloyd Haskell, Dayi Hu

Circulation· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.
Edelgard Lindhoff-Last, Jack Ansell, Theodore Spiro, Meyer Michel Samama

Ann Med· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory assessment of rivaroxaban: a review.
Meyer Michel Samama, Geneviève Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem

Thromb J· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis